EGFR and neoplasm: The humanized bsAb targeting EGFR and HER3 duligotuzumab has demonstrated tumor growth inhibition in preclinical models of NSCLC and HNSCC (head and neck squamous cell carcinoma) resistant to erlotinib and cetuximab [183].